Eli Lilly Acquires POINT Biopharma Global
December 27, 2023
Eli Lilly and Company completed the acquisition of POINT Biopharma Global Inc. after a tender offer at $12.50 per share in cash, followed by a second-step merger and delisting of POINT's common stock. The transaction brings POINT's radioligand therapy pipeline and radiopharmaceutical capabilities into Lilly's oncology research and development efforts.
- Buyers
- Eli Lilly and Company
- Targets
- POINT Biopharma Global Inc.
- Industry
- Biotechnology
- Location
- Indiana, United States
- Transaction Type
- Buyout
Explore More
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.